Bristol-Myers Squibb Co.'s pivotal CheckMate 227 data highlighted the potential for the emerging tumor mutation burden biomarker in a subset of first-line non-small cell lung cancer (NSCLC) patients to identify likely responders to its checkpoint inhibitors – but both regulators and practitioners will need to consider the role the data plays in guiding treatment.
Tumor mutation burden (TMB) refers to the number of mutations in tumor cells; a high mutation burden is thought to...